Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2026 ,inter alia, to consider and approve audited financial results for ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Parmax Pharma Ltd has informed BSE that the meeting of its Board of Directors, originally scheduled earlier, has been rescheduled to June 2, 2026. The meeting will consider and approve the audited financial results for Q4/Financial Year ended March 31, 2026. The company has also reminded that the trading window remains closed for insiders until 48 hours after the results announcement, as per SEBI Insider Trading Regulations. This is a routine procedural filing and does not contain any financial performance data.
This is a standard regulatory intimation with no direct impact on shareholders. The rescheduling of the board meeting to approve Q4/FY2026 results is a normal corporate process, and investors should await the actual financial results for any material assessment.